Ravulizumab
Modify Date: 2024-04-12 19:03:40
Ravulizumab structure
|
Common Name | Ravulizumab | ||
|---|---|---|---|---|
| CAS Number | 1803171-55-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RavulizumabRavulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1]. |
| Name | Ravulizumab |
|---|
| Description | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1]. |
|---|---|
| Related Catalog | |
| Target |
complement protein C5[1] |
| In Vitro | Ravulizumab 与 C5 高亲和力结合并抑制 C5a 和 C5b 的形成，从而防止免疫激活和溶血[1]。 |
| References |
| No Any Chemical & Physical Properties |